(Q33569305)

English

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

multicenter clinical trial

0 references

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

Alessandra Lugaresi

object named as

Alessandra Lugaresi

5

0 references

author name string

Virginia Devonshire

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Txomin Arbizu

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Bjorn Borre

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Michael Lang

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Barry Singer

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Elisabetta Verdun di Cantogno

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Peter Cornelisse

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

30 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2877661

28 July 2018

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2877661

28 July 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2877661

28 July 2018

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2877661

28 July 2018

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2877661

28 July 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2877661

28 July 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2877661

28 July 2018

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-10-28

21 January 2018

Factors that influence adherence with disease-modifying therapy in MS.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-10-28

21 January 2018

Patient satisfaction with an injection device for multiple sclerosis treatment.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-10-28

21 January 2018

Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2877661

31 October 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-10-28

21 January 2018

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20433746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20433746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20433746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20433746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2377-10-28

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dimensions Publication ID

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2377-10-28

9 September 2019

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33569305&oldid=2195501817"